Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor pharmacokinetic and pharmacodynamic study in adolescents with a central venous catheter
2012-002896-32Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in thrombosis and thromboembolism comparing Ticagrelor with Placebo (2 arms). Primary endpoint: Final extent of inhibition of platelet aggregation. Started Nov 2012; status: terminated.
02
Drugs
ticagrelor
03
Conditions
thrombosisthromboembolism
Beyond the preview
Go deeper on 2012-002896-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002896-32.